[
  {
    "ts": "2026-02-28T07:21:44+00:00",
    "headline": "Why Regeneron Pharmaceuticals (REGN) is One of the Top Gene Therapy Stocks to Buy According to Hedge Funds",
    "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the top gene therapy stocks to buy according to hedge funds. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced on February 24 that the U.S. Food and Drug Administration (FDA) approved Dupixent® (dupilumab) for the treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosinusitis with […]",
    "url": "https://finance.yahoo.com/news/why-regeneron-pharmaceuticals-regn-one-072144758.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "d56143e8-25df-3038-ac92-6e6dd051a680",
      "content": {
        "id": "d56143e8-25df-3038-ac92-6e6dd051a680",
        "contentType": "STORY",
        "title": "Why Regeneron Pharmaceuticals (REGN) is One of the Top Gene Therapy Stocks to Buy According to Hedge Funds",
        "description": "",
        "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the top gene therapy stocks to buy according to hedge funds. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced on February 24 that the U.S. Food and Drug Administration (FDA) approved Dupixent® (dupilumab) for the treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosinusitis with […]",
        "pubDate": "2026-02-28T07:21:44Z",
        "displayTime": "2026-02-28T07:21:44Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/9b67531d4ce9e2fbb21fef60675f48d3",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Regeneron (REGN) Draws Higher Target From TD Cowen",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/xYTEe3VE6sgZxe9COOwZXw--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/9b67531d4ce9e2fbb21fef60675f48d3.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ku0XeMdDvNCP8FVlwzrrCw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/9b67531d4ce9e2fbb21fef60675f48d3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/why-regeneron-pharmaceuticals-regn-one-072144758.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-regeneron-pharmaceuticals-regn-one-072144758.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "REGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-28T05:19:56+00:00",
    "headline": "Is Regeneron Pharmaceuticals Stock Underperforming the Nasdaq?",
    "summary": "Although Regeneron Pharmaceuticals has lagged the Nasdaq over the past year, analysts remain highly bullish about its prospects.",
    "url": "https://www.barchart.com/story/news/483007/is-regeneron-pharmaceuticals-stock-underperforming-the-nasdaq",
    "source": "Barchart",
    "provider": "yfinance",
    "raw": {
      "id": "bb4d6dd2-b7f4-3828-bfb9-56243ab7ffca",
      "content": {
        "id": "bb4d6dd2-b7f4-3828-bfb9-56243ab7ffca",
        "contentType": "STORY",
        "title": "Is Regeneron Pharmaceuticals Stock Underperforming the Nasdaq?",
        "description": "",
        "summary": "Although Regeneron Pharmaceuticals has lagged the Nasdaq over the past year, analysts remain highly bullish about its prospects.",
        "pubDate": "2026-02-28T05:19:56Z",
        "displayTime": "2026-02-28T05:19:56Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/barchart_com_477/b5fca612b3a61a67a2a2b488a7827af2",
          "originalWidth": 1000,
          "originalHeight": 750,
          "caption": "Regeneron Pharmaceuticals, Inc_ logo on phone-by Piotr Swat via Shutterstock",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/13cIDE5L8IVJcjoF_eSu9Q--~B/aD03NTA7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/barchart_com_477/b5fca612b3a61a67a2a2b488a7827af2.cf.webp",
              "width": 1000,
              "height": 750,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/eAqOvAl854RedqYxYy.YBw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/barchart_com_477/b5fca612b3a61a67a2a2b488a7827af2.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barchart",
          "url": "https://www.barchart.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barchart.com/story/news/483007/is-regeneron-pharmaceuticals-stock-underperforming-the-nasdaq",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/regeneron-pharmaceuticals-stock-underperforming-nasdaq-051956263.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "REGN"
            },
            {
              "symbol": "^IXIC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-28T15:07:58+00:00",
    "headline": "Intellia Therapeutics, Inc. (NTLA): A Bull Case Theory",
    "summary": "We came across a bullish thesis on Intellia Therapeutics, Inc. on Danny’s Substack by Danny Green. In this article, we will summarize the bulls’ thesis on NTLA. Intellia Therapeutics, Inc.’s share was trading at $12.48 as of February 18th. Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. NTLA represents a potentially transformative opportunity in the biotechnology space, anchored by its pioneering work in […]",
    "url": "https://finance.yahoo.com/news/intellia-therapeutics-inc-ntla-bull-150758771.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "f7aae562-f1b0-3e64-9e28-736140b8b990",
      "content": {
        "id": "f7aae562-f1b0-3e64-9e28-736140b8b990",
        "contentType": "STORY",
        "title": "Intellia Therapeutics, Inc. (NTLA): A Bull Case Theory",
        "description": "",
        "summary": "We came across a bullish thesis on Intellia Therapeutics, Inc. on Danny’s Substack by Danny Green. In this article, we will summarize the bulls’ thesis on NTLA. Intellia Therapeutics, Inc.’s share was trading at $12.48 as of February 18th. Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. NTLA represents a potentially transformative opportunity in the biotechnology space, anchored by its pioneering work in […]",
        "pubDate": "2026-02-28T15:07:58Z",
        "displayTime": "2026-02-28T15:07:58Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/3c730540d8a416c573a5dcfe934b0891",
          "originalWidth": 750,
          "originalHeight": 577,
          "caption": "Best Innovative Stocks To Buy Now",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ld07zqdlyBnAgKzAtaE8vA--~B/aD01Nzc7dz03NTA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/3c730540d8a416c573a5dcfe934b0891.cf.webp",
              "width": 750,
              "height": 577,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kIENH8kRe3pdbdiMu1V.ag--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/3c730540d8a416c573a5dcfe934b0891.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/intellia-therapeutics-inc-ntla-bull-150758771.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/intellia-therapeutics-inc-ntla-bull-150758771.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NTLA"
            },
            {
              "symbol": "REGN"
            },
            {
              "symbol": "NVS"
            },
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]